<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350844</url>
  </required_header>
  <id_info>
    <org_study_id>12735</org_study_id>
    <nct_id>NCT00350844</nct_id>
  </id_info>
  <brief_title>Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension</brief_title>
  <official_title>A Pilot Study of Hydroxyurea for the Treatment of Pulmonary Hypertension in Children and Young Adults With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test the hypothesis that hydroxyurea is effective for the
      specific treatment of secondary pulmonary hypertension found on screening in children and
      young adults with sickle cell disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing evidence suggests that pulmonary hypertension, defined by an elevated tricuspid
      regurgitant jet velocity (TRJV) on echocardiogram, is a major cause of morbidity and
      mortality in adults with sickle cell disease (SCD). However, both the prevalence and optimal
      treatment of pulmonary hypertension in children and young adults with SCD are unknown.

      We hypothesize that short term therapy with hydroxyurea will decrease TRJV in children and
      young adults with pulmonary hypertension found on screening. Patients eligible for treatment
      will have had evidence of pulmonary hypertension on at least 2 screening echocardiograms.
      Baseline laboratory tests will be obtained and other causes of secondary pulmonary
      hypertension will be excluded prior to initiation of treatment. Patients will be treated with
      hydroxyurea according to a standard dose escalation schedule for a total of 12 months. A
      clinic visit will be required every 2 months and standard screening for toxicity will be
      performed monthly. There will be an interim analysis of the primary outcome at 6 months
      following therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low subject accrual
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tricuspid Regurgitant Jet Velocity</measure>
    <time_frame>6 and 12 months after HU therapy begins</time_frame>
    <description>Primary outcome measure was tricuspid regurgitant jet velocity (TRJV) by echocardiogram after 6 and 12 months of hydroxyurea therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Throughout study</time_frame>
    <description>Secondary outcome measures included compliance; laboratory measures of therapy-related toxicity; laboratory biomarkers for hemolysis, oxidative stress and endothelial injury; and quality of life measures by Child Health Questionnaire (CHQ).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.</description>
    <arm_group_label>Hydroxyurea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 10 and 25 years old

          -  Sickle cell disease with hemoglobin SS, SC or S-B^0 thalassemia confirmed on
             hemoglobin electrophoresis

          -  Tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2
             baseline Doppler echocardiograms at least 3 months apart

        Exclusion Criteria:

          -  Patients already being treated with hydroxyurea

          -  Patients on a chronic transfusion protocol

          -  Patients with evidence of hepatic (alanine aminotransferase [ALT] equal to or greater
             than 2 SD above normal) or renal dysfunction (creatinine [Cr] equal to or greater than
             2 SD above normal)

          -  Patients who are pregnant

          -  Patients with documented causes of severe pulmonary hypertension other than from SCD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert I Liem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614-3394</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2006</study_first_posted>
  <results_first_submitted>February 18, 2013</results_first_submitted>
  <results_first_submitted_qc>March 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2013</results_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Robert I. Liem</investigator_full_name>
    <investigator_title>MD, Assistant Professor of Pediatics, NU Feinberg School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study is currently closed to patient accrual at all sites due to poor enrollment, including Childrenâ€™s Memorial Hospital, Washington University, Johns Hopkins and the Medical College of Wisconsin. The FDA was notified in 2010, and the IND was removed for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydroxyurea</title>
          <description>Hydroxyurea : 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxyurea</title>
          <description>Hydroxyurea : 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Study was terminated due to low enrollment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tricuspid Regurgitant Jet Velocity</title>
        <description>Primary outcome measure was tricuspid regurgitant jet velocity (TRJV) by echocardiogram after 6 and 12 months of hydroxyurea therapy.</description>
        <time_frame>6 and 12 months after HU therapy begins</time_frame>
        <population>Study was terminated and 0 participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Hydroxyurea : 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Tricuspid Regurgitant Jet Velocity</title>
          <description>Primary outcome measure was tricuspid regurgitant jet velocity (TRJV) by echocardiogram after 6 and 12 months of hydroxyurea therapy.</description>
          <population>Study was terminated and 0 participants were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance</title>
        <description>Secondary outcome measures included compliance; laboratory measures of therapy-related toxicity; laboratory biomarkers for hemolysis, oxidative stress and endothelial injury; and quality of life measures by Child Health Questionnaire (CHQ).</description>
        <time_frame>Throughout study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydroxyurea</title>
          <description>Hydroxyurea : 20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to no data analysis completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Robert I. Liem</name_or_title>
      <organization>Ann and Robert H. Lurie Children's Hospital of Chicago</organization>
      <phone>312-227-4842</phone>
      <email>Rliem@luriechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

